BioElectronics Corporation BIEL

Company Overview

BioElectronics Corporation (OTC: BIEL) is a medical device company focused on non-invasive electroceutical technologies for pain management and recovery. The company develops and markets wearable pulsed shortwave therapy devices designed to reduce pain, inflammation, and edema without pharmaceuticals. BioElectronics operates within the medical technology, consumer healthcare, and electroceutical therapy industries, with products primarily targeting musculoskeletal pain, postoperative recovery, and chronic pain conditions.

The company’s primary revenue drivers have historically included sales and licensing of its flagship products, including ActiPatch, RecoveryRx, and related wearable therapy devices that use pulsed electromagnetic field (PEMF) or pulsed shortwave therapy technology. BioElectronics has positioned itself as a low-cost, over-the-counter alternative to certain pharmaceutical pain treatments, particularly amid broader healthcare interest in non-opioid pain management solutions. Founded in 2000, the company evolved from a small medical technology developer into a niche electroceutical device provider pursuing both direct-to-consumer and distribution-based commercialization strategies. Public disclosures indicate that commercialization efforts and regulatory access have been central to its business evolution.

Business Operations

BioElectronics conducts operations primarily through the development, manufacturing coordination, commercialization, and licensing of wearable pain therapy devices. The company’s business model has included direct product sales, distributor relationships, private-label arrangements, and strategic licensing opportunities. Its core assets are its patented pulsed shortwave therapy technologies and related intellectual property portfolio supporting wearable medical devices. Public filings indicate that the company has relied heavily on external manufacturing and distribution partnerships rather than large-scale internal manufacturing infrastructure.

Operations have historically focused on the United States while also pursuing international distribution opportunities in parts of Europe, Asia, and other global healthcare markets. BioElectronics has referenced relationships with medical distributors, retail partners, and healthcare-oriented commercial channels in public disclosures, although some partnership details have changed over time and certain agreements have not remained continuously active. Data regarding the scale and financial contribution of individual international operations is limited based on available public sources.

Strategic Position & Investments

BioElectronics’ strategic direction has centered on expanding adoption of non-invasive electroceutical therapy as an alternative or complement to drug-based pain treatment. The company has emphasized regulatory advancement, broader retail distribution, and increased physician awareness as key growth initiatives. Public filings and investor materials have also highlighted efforts to expand commercialization of ActiPatch and RecoveryRx into additional healthcare and consumer channels, particularly in response to growing interest in opioid-free pain management technologies.

The company’s investment profile has primarily involved research and development, intellectual property protection, and commercialization activities rather than large-scale acquisitions. Unlike larger medical technology firms, BioElectronics has not publicly disclosed significant acquisition-driven expansion strategies. Its strategic value proposition is tied to patented wearable electroceutical technology, relatively low-cost therapy delivery, and over-the-counter accessibility in certain markets. Publicly available information does not indicate a broad portfolio of subsidiaries or major controlled portfolio companies. Data inconclusive based on available public sources regarding material joint ventures or significant equity investments.

Geographic Footprint

BioElectronics is headquartered in Frederick, Maryland, United States, and its operational focus has historically been concentrated in the United States market. The company has also pursued international distribution and commercialization opportunities through third-party partners in regions including Europe, Asia, and parts of the Middle East. Public disclosures reference international sales activity, though detailed regional revenue segmentation has been limited in available filings.

The company’s products have been marketed internationally through distributor networks and licensing arrangements rather than extensive owned operational infrastructure abroad. BioElectronics’ global presence remains comparatively modest relative to major multinational medical device companies, with international influence tied primarily to product distribution and regulatory access initiatives.

Leadership & Governance

BioElectronics was founded by Andrew J. Whelan, who has played a significant role in the company’s strategic and technological development. Leadership has historically emphasized expanding awareness of electroceutical therapy and positioning wearable pulsed shortwave technology within the broader non-opioid pain management market. Public filings indicate that governance and executive leadership have evolved over time alongside the company’s financing and commercialization activities.

Key executives and leadership figures identified in public filings and company disclosures include:

• Andrew J. Whelan – Chairman and Chief Executive Officer
• Kelly Whelan – President
• Richard Staelin – Director
• Anthony K. Amato – Director

Publicly available governance information for BioElectronics is more limited than that of larger exchange-listed medical technology companies due to its OTC market status and reporting profile. Certain executive and board role details may vary across reporting periods and disclosures.